Shah Discusses Hope for CAR T-Cell Therapy in Multiple Myeloma
Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.
Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the question of whether chimeric antigen receptor (CAR) T-cell therapy is ready for primetime in patients with multiple myeloma.
Shah says it is not primetime for CAR T cells in multiple myeloma yet, but the reason for asking this question is because of the significant responses that have been demonstrated with CAR T cells already in this space. The therapy induced response rates around 85% to 90% in patients who are heavily pretreated with multiple myeloma, where the median number of prior lines is 7. These kind of response rates are unheard of in this patient population, Shah says, and CAR T-cell therapy is ultimately rescuing a lot of really sick patients.
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
December 10th 2023Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
Read More
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Read More
Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Read More
